Cargando…
S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428490/ http://dx.doi.org/10.1097/01.HS9.0000967792.43327.c1 |
| _version_ | 1785090482845515776 |
|---|---|
| author | Ahmed, Nausheen Kambhampati, Swetha Hamadani, Mehdi Grover, Natalie Shadman, Mazyar Locke, Frederick Gerson, James Frank, Matthew J. Budde, L. Elizabeth Wang, Michael Hu, Zhen-Huan Nunes, Ana Dalton, David Kloos, Ioana Lee, Daniel Xu, Hairong Pasquini, Marcelo Herrera, Alex F. |
| author_facet | Ahmed, Nausheen Kambhampati, Swetha Hamadani, Mehdi Grover, Natalie Shadman, Mazyar Locke, Frederick Gerson, James Frank, Matthew J. Budde, L. Elizabeth Wang, Michael Hu, Zhen-Huan Nunes, Ana Dalton, David Kloos, Ioana Lee, Daniel Xu, Hairong Pasquini, Marcelo Herrera, Alex F. |
| author_sort | Ahmed, Nausheen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428490 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104284902023-08-17 S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT Ahmed, Nausheen Kambhampati, Swetha Hamadani, Mehdi Grover, Natalie Shadman, Mazyar Locke, Frederick Gerson, James Frank, Matthew J. Budde, L. Elizabeth Wang, Michael Hu, Zhen-Huan Nunes, Ana Dalton, David Kloos, Ioana Lee, Daniel Xu, Hairong Pasquini, Marcelo Herrera, Alex F. Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428490/ http://dx.doi.org/10.1097/01.HS9.0000967792.43327.c1 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Ahmed, Nausheen Kambhampati, Swetha Hamadani, Mehdi Grover, Natalie Shadman, Mazyar Locke, Frederick Gerson, James Frank, Matthew J. Budde, L. Elizabeth Wang, Michael Hu, Zhen-Huan Nunes, Ana Dalton, David Kloos, Ioana Lee, Daniel Xu, Hairong Pasquini, Marcelo Herrera, Alex F. S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT |
| title | S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT |
| title_full | S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT |
| title_fullStr | S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT |
| title_full_unstemmed | S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT |
| title_short | S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT |
| title_sort | s220: real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory mantle cell lymphoma: a cibmtr subgroup analysis by prior treatment |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428490/ http://dx.doi.org/10.1097/01.HS9.0000967792.43327.c1 |
| work_keys_str_mv | AT ahmednausheen s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT kambhampatiswetha s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT hamadanimehdi s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT grovernatalie s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT shadmanmazyar s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT lockefrederick s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT gersonjames s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT frankmatthewj s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT buddelelizabeth s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT wangmichael s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT huzhenhuan s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT nunesana s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT daltondavid s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT kloosioana s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT leedaniel s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT xuhairong s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT pasquinimarcelo s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT herreraalexf s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment |